PharmaEngine, Inc.

Taipei Exchange 4162.TWO

PharmaEngine, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: 45.57

PharmaEngine, Inc. Price to Earnings Ratio (P/E) is 45.57 on January 14, 2025, a -14.62% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

PharmaEngine, Inc. 52-week high Price to Earnings Ratio (P/E) is 56.33 on February 15, 2024, which is 23.60% above the current Price to Earnings Ratio (P/E).
PharmaEngine, Inc. 52-week low Price to Earnings Ratio (P/E) is 39.45 on August 06, 2024, which is -13.44% below the current Price to Earnings Ratio (P/E).
PharmaEngine, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is 46.82.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Taipei Exchange: 4162.TWO

PharmaEngine, Inc.

CEO	Mr. Hong-Ren Wang Ph.D.
IPO Date	June 20, 2012
Location	Taiwan
Headquarters	10 Minsheng East Road
Employees	17
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

Key trends

Past 5 years